Special Use Investigation of HALAVEN (HAL03T) - Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas

Trial Profile

Special Use Investigation of HALAVEN (HAL03T) - Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Eribulin (Primary)
  • Indications Soft tissue sarcoma
  • Focus Adverse reactions
  • Acronyms HAL03T
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 26 Jun 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Nov 2018.
    • 22 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top